Biologics World Korea: Counting On A Paradigm Shift In Biologics Market
This article was originally published in PharmAsia News
Biopharmaceutical experts from around the world gathered in Seoul at the recent Biologics World Korea 2015, at which a group of panelists discussed the strategic direction of the biologics industry in Asia and a paradigm shift in the global biologics market.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.